



## **MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes**

December 15, 2008 5:00 AM EST

### **MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes**

VALENCIA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will host a live broadcast to review clinical results from its final two Phase 3 studies of AFRESA, the company's ultra rapid acting, inhaled insulin product, at 9 a.m. Eastern Time on Thursday, December 18, 2008.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in viewing the live webcast via the Internet may do so by visiting the Company's website at <http://www.mannkindcorp.com>.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 873-5860 or (203) 369-3996. A replay will also be available on MannKind's website for fourteen days.

#### About AFRESA

Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The pharmacokinetic profile of Afresa sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive Afresa particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

#### About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

#### SOURCE MannKind Corporation

#### CONTACT:

Matthew J. Pfeffer,  
Corporate Vice President and Chief Financial Officer of  
MannKind Corporation,  
+1-661-775-5300,  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)

Web Site: <http://www.mannkindcorp.com>